index,P,I,C,O,S,matches_criteria,reasoning
0,patients with high-risk surgically resected or ablated hepatocellular carcinoma,atezolizumab plus bevacizumab,active surveillance,recurrence-free survival,randomized controlled trial,True,matches all target PICOS criteria
1,patients with advanced biliary tract cancer,pembrolizumab plus gemcitabine and cisplatin,placebo plus gemcitabine and cisplatin,overall survival,randomized controlled trial,False,population does not match target criteria
2,patients with unresectable hepatocellular carcinoma,STRIDE (Single Tremelimumab Regular Interval Durvalumab),sorafenib,overall survival,randomized controlled trial,True,matches all target PICOS criteria
3,patients with unresectable or metastatic hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,progression-free survival and overall survival,randomized controlled trial,True,matches all target PICOS criteria
4,HCC patients in BCLC stage C,camrelizumab and apatinib with HAIC-FOLFOX,not specified,objective response rate,not specified,False,comparison and study design not specified
5,patients with unresectable hepatocellular carcinoma,tislelizumab,sorafenib tosylate,overall survival,randomized controlled trial,True,matches all target PICOS criteria
6,not specified,not specified,not specified,liver disease risk,observational study,False,does not match target PICOS criteria
7,patients with unresectable hepatocellular carcinoma,tremelimumab in combination with durvalumab,not specified,overall survival,not specified,False,comparison and study design not specified
8,patients with unresectable hepatocellular carcinoma,lenvatinib plus pembrolizumab,lenvatinib plus placebo,overall survival and progression-free survival,randomized controlled trial,True,matches all target PICOS criteria
9,adults with MASLD without cirrhosis,low-dose aspirin,placebo,hepatic fat content,randomized controlled trial,False,population does not match target criteria
60,patients with hepatocellular carcinoma,palliative care intervention,standard of care,symptom improvement,randomized controlled trial,False,"Intervention is palliative care, not immunotherapy or targeted therapy."
61,people with HIV,antiretroviral therapy,not specified,cause-specific mortality,observational cohort study,False,Population is not hepatocellular carcinoma patients; study design is not RCT.
62,patients with hepatocellular carcinoma,liver resection,not specified,overall survival,retrospective study,False,"Intervention is surgical, not immunotherapy or targeted therapy; study design is not RCT."
63,patients with hepatocellular carcinoma,contrast-enhanced US,CE MRI or CT,detection of residual viable HCC,prospective multicenter trial,False,"Intervention is diagnostic, not therapeutic; study design is not RCT."
64,patients with hepatocellular carcinoma,hepatectomy,not specified,postoperative complications and long-term outcomes,retrospective study,False,"Intervention is surgical, not immunotherapy or targeted therapy; study design is not RCT."
65,patients with recurrent intermediate-stage HCC,SOR-TACE,TACE alone,overall survival,randomized clinical trial,True,Matches all target PICOS criteria.
66,patients with advanced hepatocellular carcinoma,nivolumab plus ipilimumab,not specified,overall survival and response rate,randomized controlled trial,True,Matches all target PICOS criteria.
67,patients with advanced HCC and extrahepatic metastasis,FOLFOX4-ATRA,FOLFOX4-placebo,overall survival,"randomized, double-blind, placebo-controlled study",False,"Intervention is chemotherapy, not immunotherapy or targeted therapy."
68,patients with early-stage resectable HCC,neoadjuvant PD-1 blockade plus SBRT,not specified,tumor response and safety,phase 1b trial,False,"Study design is phase 1b trial, not RCT."
69,patients with hepatocellular carcinoma,not specified,not specified,prognosis and survival,prospective cohort study,False,Intervention not specified; study design is not RCT.
10,patients with small hepatocellular carcinoma,laparoscopic liver resection,radiofrequency ablation,overall survival and recurrence-free survival,randomized controlled trial,False,Intervention and comparison do not match the target criteria of immunotherapy or targeted therapy versus standard therapy or placebo.
11,patients with advanced hepatocellular carcinoma,Lenvatinib combined with transarterial chemoembolization,Lenvatinib monotherapy,overall survival,randomized controlled trial,False,Intervention and comparison do not match the target criteria of immunotherapy or targeted therapy versus standard therapy or placebo.
12,patients at risk of hepatocellular carcinoma,not specified,not specified,prediction of HCC development,observational study,False,"Does not meet the target criteria for intervention, comparison, outcome, or study design."
13,patients with autoimmune hepatitis,not specified,not specified,risk of hepatocellular carcinoma,retrospective observational study,False,"Does not meet the target criteria for intervention, comparison, outcome, or study design."
14,HCC patients with microvascular invasion,postoperative adjuvant hepatic arterial infusion chemotherapy,routine follow-up,disease-free survival,randomized controlled trial,False,Intervention and comparison do not match the target criteria of immunotherapy or targeted therapy versus standard therapy or placebo.
15,patients with advanced solid tumours,cadonilimab monotherapy,not specified,objective response rate,phase 1b/2 trial,False,Population and outcome do not match the target criteria.
16,patients with unresectable HCC,Lenvatinib plus anti-PD-1 antibodies,not specified,conversion success rate,single-arm phase II study,False,Comparison and study design do not match the target criteria.
17,patients with locally advanced HCC,TACE and stereotactic body radiotherapy followed by avelumab,not specified,proportion of patients amenable to curative treatment,single-arm phase 2 trial,False,Comparison and study design do not match the target criteria.
18,patients with advanced HCC,pembrolizumab,placebo,overall survival,double-blind phase III trial,True,"Meets all target criteria: population, intervention, comparison, outcome, and study design."
19,patients with HCC,Atezolizumab plus bevacizumab,not specified,progression-free survival and overall survival,real-world setting analysis,False,Comparison and study design do not match the target criteria.
40,patients with hepatocellular carcinoma,not specified,not specified,overall and progression-free survival,retrospective observational study,False,Intervention and comparison not specified; study design does not match
41,patients with unresectable hepatocellular carcinoma,"STRIDE regimen, durvalumab",sorafenib,patient-reported outcomes including quality of life,randomized controlled trial,True,Matches all PICOS criteria
42,patients with hepatocellular carcinoma,not specified,not specified,overall and cancer-specific survival,retrospective study,False,Intervention and comparison not specified; study design does not match
43,patients with surgically treated hepatocellular carcinoma,not specified,not specified,early relapse and survival,retrospective analysis,False,Intervention and comparison not specified; study design does not match
44,HCC patients undergoing hepatic resection,virtual reality education program,conventional explanation processes,anxiety and knowledge about liver resection,randomized controlled trial,False,Population and intervention do not match target criteria
45,HCC patients with Child-Pugh score 5 undergoing liver resection,not specified,not specified,post-hepatectomy liver failure,retrospective study,False,Intervention and comparison not specified; study design does not match
46,adult patients with unresectable hepatocellular carcinoma,tremelimumab in combination with durvalumab,sorafenib,overall survival,randomized controlled trial,True,Matches all PICOS criteria
47,patients with advanced or unresectable hepatocellular carcinoma,SBRT followed by nivolumab alone or plus ipilimumab,not specified,"overall survival, progression-free survival",multicenter phase 1 randomized trial,False,Comparison not specified
48,HCC patients exceeding the Milan criteria,neoadjuvant pembrolizumab plus lenvatinib,control group,recurrence-free survival after liver transplantation,"prospective, randomized, open-label, pilot study",False,Population does not match target criteria
49,patients with unresectable hepatocellular carcinoma,stereotactic body radiotherapy,not specified,"progression-free survival, overall survival",phase 2 nonrandomized controlled trial,False,Comparison not specified; study design does not match
20,patients with advanced hepatocellular carcinoma,sitravatinib with/without tislelizumab,not specified,objective response rate,phase Ib/II study,False,"No comparison to standard therapy or placebo specified; study design is phase Ib/II, not randomized controlled trial"
21,patients with advanced HCC previously treated with a multityrosine kinase inhibitor,DNA plasmid PTCV plus pembrolizumab,not specified,objective response rate,"single-arm, open-label, phase 1/2 study",False,"No comparison to standard therapy or placebo specified; study design is single-arm, not randomized controlled trial"
22,people living with HBV and T2DM,not specified,not specified,burden of liver cancer,observational study,False,"Population does not match; no intervention, comparison, or randomized controlled trial design specified"
23,patients with HCC with MVI,adjuvant sintilimab,active surveillance,recurrence-free survival,"randomized, controlled, phase 2 trial",True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design"
24,cancer patients with irAE-n,not specified,not specified,immune cell dysregulation,observational cohort study,False,"Population does not match; no intervention, comparison, or randomized controlled trial design specified"
25,patients with localized early HCC,radiation therapy,not specified,local control and adverse events,not specified,False,No comparison to standard therapy or placebo specified; study design not specified
26,patients with unresectable hepatocellular carcinoma,regorafenib-nivolumab,not specified,objective response rate,"single-arm, phase 2 trial",False,"No comparison to standard therapy or placebo specified; study design is single-arm, not randomized controlled trial"
27,patients with hepatocellular carcinoma or liver metastases,single-fraction radiotherapy,best supportive care,improvement in hepatic pain,"randomized, controlled, phase 3 trial",True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design"
28,patients with T2D and concomitant NAFLD,"SGLT2 inhibitors, thiazolidinediones, DPP-4 inhibitors, or sulfonylureas",not specified,NAFLD regression and liver-related outcomes,retrospective nonrandomized interventional cohort study,False,Population does not match; no comparison to standard therapy or placebo specified; study design is not randomized controlled trial
29,liver cirrhosis patients,not specified,not specified,identification of non-invasive biomarkers,prospective study,False,"Population does not match; no intervention, comparison, or randomized controlled trial design specified"
30,patients with hepatocellular carcinoma,endoscopic variceal ligation or propranolol,endoscopic variceal ligation vs propranolol,overall survival and variceal bleeding,randomized controlled trial,False,intervention does not match immunotherapy or targeted therapy
31,patients with mild-to-moderate Covid-19,simnotrelvir plus ritonavir,simnotrelvir plus ritonavir vs placebo,time to sustained resolution of symptoms,randomized controlled trial,False,population does not match hepatocellular carcinoma
32,patients with locally advanced unresectable HCC,Y90-radioembolization and durvalumab,not specified,"time to progression, overall survival, progression-free survival, objective response rate",phase I/IIa pilot trial,True,matches all PICOS criteria
33,patients with unresectable HCC,lenvatinib vs atezolizumab plus bevacizumab,lenvatinib vs atezolizumab plus bevacizumab,overall survival,retrospective multi-centre study,False,study design does not match randomized controlled trial
34,patients with advanced hepatocellular carcinoma,nivolumab plus cabozantinib with or without ipilimumab,nivolumab plus cabozantinib vs nivolumab plus cabozantinib with ipilimumab,"objective response rate, duration of response, progression-free survival, overall survival",phase I/II study,True,matches all PICOS criteria
35,patients with unresectable HCC,UCPVax vaccine with atezolizumab and bevacizumab,not specified,objective response rate,multicenter randomized phase II study,False,comparison not specified
36,patients with advanced hepatocellular carcinoma,nivolumab monotherapy,not specified,"objective response rate, overall survival",phase I/II study,False,comparison not specified
37,patients with HCC refractory to prior ICI-based treatment,cabozantinib,not specified,"progression-free survival, overall survival",phase II clinical trial,False,comparison not specified
38,patients with recurrent or oligometastatic HCC,SBRT plus sintilimab,not specified,"progression-free survival, overall survival",clinical trial,False,comparison not specified
39,"patients with hepatocellular carcinoma in Ceará, Brazil","liver transplantation, transarterial chemoembolization",not specified,"hepatocellular carcinoma recurrence, treatment outcomes",retrospective observational study,False,study design does not match randomized controlled trial
70,postmenopausal women,diabetes risk reduction diet,not specified,liver cancer incidence and chronic liver disease mortality,observational study,False,Population does not match; intervention and comparison do not match target criteria; study design is not a randomized controlled trial.
71,patients with advanced intrahepatic cholangiocarcinoma,"toripalimab, lenvatinib, and GEMOX",not specified,"objective response rate, overall survival, progression-free survival","phase-III, multicenter, double-blinded, randomized study",False,Population does not match; intervention partially matches but not specific to hepatocellular carcinoma; study design matches.
72,HCC patients,TACE and HAIC,not specified,impact on liver function,not specified,False,Population matches; intervention does not match target criteria; outcome and study design do not match.
73,patients with HCC,DEB-TACE,not specified,acute liver function deterioration,not specified,False,Population matches; intervention does not match target criteria; outcome and study design do not match.
74,patients with advanced HCC,atezolizumab/bevacizumab,not specified,organ-specific responses,"retrospective, multicenter, observational study",False,Population matches; intervention matches; outcome and study design do not match.
75,patients with HCC,atezolizumab and bevacizumab with tiragolumab or placebo,placebo,clinical benefit,"randomized, double-blind, placebo-controlled Phase III study",True,"Population, intervention, comparison, outcome, and study design match target criteria."
76,patients with advanced HCC,SIRT/Sorafenib treatment,sorafenib,overall survival,subanalysis of the SORAMIC trial,False,Population matches; intervention and comparison partially match; outcome matches; study design does not match.
77,patients with hepatocellular carcinoma with portal vein tumor thrombus,sorafenib plus transarterial chemoembolization,sorafenib alone,recurrence-free survival and overall survival,"phase 3, multicenter, randomized clinical trial",True,"Population, intervention, comparison, outcome, and study design match target criteria."
78,patients with locally advanced or metastatic HCC,BLU-554 combined with CS1001,not specified,objective response rate,Phase Ib/II trial,False,Population matches; intervention matches; comparison not specified; outcome matches; study design partially matches.
79,patients at high risk of HCC,low-contrast-dose CT using dual-energy CT and deep learning-based denoising,standard-contrast-dose CT,HCC conspicuity,"prospective, randomized controlled noninferiority trial",False,Population matches; intervention and comparison do not match target criteria; outcome and study design do not match.
50,patients at stage IV of HCC,development of nomogram models,not specified,cancer-specific survival,retrospective cohort study,False,"Does not match target criteria: no intervention of immunotherapy or targeted therapy, no comparison, not a randomized controlled trial."
51,individuals with unresectable HCC,systemic anti-angiogenic therapy,not specified,overall survival,phase III study,False,"Does not match target criteria: intervention is not immunotherapy or targeted therapy, no comparison, not a randomized controlled trial."
52,outpatient patients with HCC,oral targeted therapy,not specified,nonadherence status,prospective observational study,False,"Does not match target criteria: no comparison, outcome is not survival or response rate, not a randomized controlled trial."
53,patients with previously untreated advanced HCC,cabozantinib plus atezolizumab,sorafenib,overall survival and progression-free survival,"randomized, phase 3 study",True,"Matches target criteria: population, intervention, comparison, outcome, and study design all align with target criteria."
54,patients with HCC,not specified,not specified,diagnosis of liver cirrhosis,not specified,False,"Does not match target criteria: no intervention, no comparison, outcome not related to survival or response rate, study design not specified."
55,"patients with refractory solid tumors, including HCC",navitoclax plus sorafenib,not specified,safety and efficacy,phase 1 study,False,"Does not match target criteria: no comparison, outcome not specifically survival or response rate, not a randomized controlled trial."
56,patients with advanced HCC,cadonilimab plus lenvatinib,not specified,"objective response rate, safety, progression-free survival, overall survival",phase Ib/II study,False,"Does not match target criteria: no comparison, not a randomized controlled trial."
57,patients with advanced HCC with extrahepatic metastasis,FOLFOX chemotherapy plus lenvatinib and toripalimab,not specified,"progression-free survival, overall survival, objective response rate",phase II trial,False,"Does not match target criteria: no comparison, not a randomized controlled trial."
58,patients with HCC,antidepressant use,not specified,overall and cancer-specific mortality,population-based cohort study,False,"Does not match target criteria: intervention not immunotherapy or targeted therapy, no comparison, not a randomized controlled trial."
59,patients with chronic hepatitis B infection or cirrhosis,ultrasound-based vs. biomarker-based screening,not specified,reduction in late-stage HCC,adaptive pragmatic randomized phase IV trial,False,"Does not match target criteria: intervention not related to treatment, no comparison, outcome not survival or response rate."
100,patients with hepatitis B,nurse-led decision counselling programme,usual care,hepatocellular carcinoma screening rate,single-blind randomised controlled trial,False,Population does not match; intervention and outcome do not match target criteria.
101,patients with hepatocellular carcinoma,fostroxacitabine bralpamide,not specified,"safety, preliminary efficacy","open-label, single-arm, phase 1a/1b study",False,Comparison and outcome do not match target criteria; study design is not randomized controlled trial.
102,CHB patients with elevated cholesterol levels,statin therapy,statin non-user,development of HCC,observational data to emulate a target trial,False,Population and intervention do not match; study design is not randomized controlled trial.
103,patients diagnosed with HCC,DEB-TACE using small-size microspheres,not specified,6-month objective response rate,"prospective, single-arm, multicenter study",False,Comparison and outcome do not match; study design is not randomized controlled trial.
104,patients with advanced-stage HCC,ICIs combined with antiangiogenic therapy,non-radiation therapy,"progression-free survival, overall survival",retrospective observational study,False,Study design is not randomized controlled trial.
105,patients with malignant ascites,oncolytic adenovirus H101,not specified,efficacy and safety,phase II trial,False,"Population, intervention, and outcome do not match; study design is not randomized controlled trial."
106,patients with a solitary HCC,SABR,thermal ablation or best standard of care therapy,freedom from local progression,"phase II, prospective, randomised trial",True,Matches all target PICOS criteria.
107,patients with intermediate/advanced HCC,adjuvant immune checkpoint inhibitors,without adjuvant immunotherapy,"recurrence-free survival, overall survival",prospectively-collected multicenter database,False,Study design is not randomized controlled trial.
108,patients with advanced hepatocellular carcinoma,OBP-301,not specified,safety and optimal dosage,phase I dose-escalation trial,False,Comparison and outcome do not match; study design is not randomized controlled trial.
109,patients with HCC,proton beam radiotherapy,transarterial chemoembolization,overall survival,randomized,True,Matches all target PICOS criteria.
80,patients at high-risk for hepatocellular carcinoma,deep-learning-based contrast-boosting algorithm on double-low-dose CT,standard-dose CT,"contrast-to-noise ratio, image quality, lesion detection rate",randomized controlled trial,False,"Population and study design match, but intervention and outcomes do not match the target criteria."
81,patients with large or huge hepatocellular carcinoma,transcatheter arterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide,conventional transcatheter arterial chemoembolization,"progression-free survival, overall survival, treatment response",randomized controlled trial,True,All PICOS elements match the target criteria.
82,patients with hepatocellular carcinoma previously treated with chemoembolization or yttrium-90 resin transarterial radioembolization,yttrium-90 resin transarterial radioembolization,chemoembolization,"overall survival, best response, toxicities",prospective observational study,False,"Population and outcomes match, but intervention and study design do not match the target criteria."
83,individuals attending a health center in Cameroon,not specified,not specified,association between anti-HCV positivity and liver impairment,facility-based observational study,False,Population and study design do not match the target criteria.
84,patients with hepatocellular carcinoma with portal vein tumor thrombus,sintilimab plus bevacizumab combined with radiotherapy,not specified,"objective response rate, overall survival, progression-free survival","open-label, multicenter, single-arm, phase 2 clinical trial",False,"Population and outcomes match, but intervention and study design do not match the target criteria."
85,patients with unresectable hepatocellular carcinoma,bavituximab plus pembrolizumab,not specified,"objective response rate, progression-free survival, overall survival",single-arm phase 2 trial,False,"Population and outcomes match, but intervention and study design do not match the target criteria."
86,patients with histologically proven BCLC-B/C hepatocellular carcinoma without previous systemic therapy,ipilimumab plus atezolizumab/bevacizumab,atezolizumab/bevacizumab,"objective response rate, overall survival, progression-free survival","multicentre, randomised, open-label phase II-III trial",True,All PICOS elements match the target criteria.
87,patients with hepatocellular carcinoma,acyclic retinoid,not specified,"HCC recurrence, long-term HCC prognosis",phase 3 clinical trial,False,"Population and outcomes match, but intervention and study design do not match the target criteria."
88,patients with cirrhosis in a multicenter randomized trial of HCC surveillance outreach,not specified,not specified,psychological harms of HCC surveillance,multicenter randomized trial,False,Population and study design do not match the target criteria.
89,patients undergoing liver transplantation,hypothermic oxygenated machine perfusion,static cold storage,"early allograft dysfunction, graft failure, biliary strictures","multicenter, randomized, open-label, noninferiority trial",False,Population and study design do not match the target criteria.
120,patients with hepatocellular carcinoma,transarterial chemoembolization (TACE),not specified,progression-free survival (PFS) and TACE treatment response,prospective single-center observational study,False,"Intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
121,patients with advanced hepatocellular carcinoma,radiotherapy combined with tislelizumab and anlotinib,not specified,overall survival (OS) and progression-free survival (PFS),not specified,False,"Comparison is not specified, and study design is not a randomized controlled trial."
122,Hepatocellular carcinoma patients with macrovascular invasion,perioperative tislelizumab plus intensity modulated radiotherapy (IMRT),not specified,overall response rate (ORR) and overall survival (OS),phase 2 trial,False,"Comparison is not specified, and study design is a phase 2 trial, not a randomized controlled trial."
123,patients with cirrhosis undergoing TIPS,recompensation after TIPS,compensated cirrhosis patients,risk of hepatocellular carcinoma (HCC) and death,observational study,False,"Population is not specifically hepatocellular carcinoma patients, and study design is not a randomized controlled trial."
124,HCC patients,computed tomography (CT)-based conventional radiomics and deep-learning convolutional neural networks (CNN),not specified,overall survival (OS),retrospective study,False,"Intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
125,HBV-related HCC patients after curative liver resection,TDF therapy,ETV therapy,tumor recurrence and overall survival,randomized controlled trial,False,Intervention is not immunotherapy or targeted therapy.
126,US adults ages ≥ 21 years,alcohol warning messages,control topic (recycling or reselling products),perceived message effectiveness and reactance,online within-subjects experiment,False,"Population is not hepatocellular carcinoma patients, and intervention is not related to the specified criteria."
127,patients with unresectable HCC,Tislelizumab,Sorafenib,cost-effectiveness and quality-adjusted life-years (QALYs),partitioned survival model (PSM),False,"Outcome is not survival or response rate, and study design is not a randomized controlled trial."
128,HCC and fibrolamellar carcinoma (FLC) patients,liver resection,not specified,overall survival (OS),retrospective analysis,False,"Intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
129,HBV-compensated cirrhosis patients with small/medium EV,carvedilol plus NUC,NUC alone,progression rate of EV and liver-related events,randomized controlled trial,False,"Population is not specifically hepatocellular carcinoma patients, and outcome is not survival or response rate."
130,patients with hepatocellular carcinoma undergoing liver resection,administration of dexamethasone before clamping the hilar pedicle,placebo,"postoperative liver function, inflammatory response, and perioperative outcomes","randomized, dual-arm, parallel-group, double-blinded trial",False,"Population and study design match, but intervention and outcome do not match the target criteria."
131,patients with dual-phenotype hepatocellular carcinoma and non-DPHCC,clinical and radiomics models based on contrast-enhanced MRI,not specified,diagnostic performance of MRI radiomics models,retrospective,False,"Population does not match, and study design is not a randomized controlled trial."
132,patients with unresectable hepatocellular carcinoma,TACE combined with envafolimab and lenvatinib,not specified,"objective response rate, disease control rate, progression-free survival",not specified,False,"Population matches, but intervention, comparison, and study design do not match the target criteria."
133,patients with advanced liver cancer,novel antisense oligonucleotide drug targeting human IGF-1R,not specified,tolerability and safety of the drug,dose-escalation trial,False,"Population matches, but intervention, comparison, outcome, and study design do not match the target criteria."
134,patients with nonoperable locally advanced hepatocellular carcinoma,(90)Y-loaded glass microspheres with personalized dosimetry,standard dosimetry,overall survival,"phase II study, randomized",True,All PICOS elements match the target criteria.
135,patients with liver-confined hepatocellular carcinoma,TACE plus pembrolizumab,not specified,"safety, progression-free survival, overall survival",not specified,False,"Population and intervention partially match, but comparison, outcome, and study design do not match the target criteria."
136,patients with intermediate-stage hepatocellular carcinoma,NAC and DEXA combination,placebo,prevention of PES and liver decompensation after cTACE,"prospective, randomized",False,"Population and study design match, but intervention and outcome do not match the target criteria."
137,patients with HCC with extrahepatic metastasis,apatinib with hepatic arterial infusion chemotherapy,not specified,"objective response rate, progress-free survival, overall survival",phase II trial,False,"Population matches, but intervention, comparison, and study design do not match the target criteria."
138,patients with cirrhosis and HCC,TARE with (131)I-lipiodol,TACE,"objective tumor response, survival",prospective clinical trials,False,"Population and comparison match, but intervention, outcome, and study design do not match the target criteria."
139,patients with hepatocellular carcinoma,not specified,not specified,overall survival according to sex,retrospective,False,"Population matches, but intervention, comparison, outcome, and study design do not match the target criteria."
110,patients with hepatocellular carcinoma,intraperitoneal anti-PD-1 antibody,not specified,"safety, objective response rate, ascites control rate, overall survival",phase Ib study,False,"Population and intervention match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
111,patients with advanced hepatocellular carcinoma,pembrolizumab plus Y90 radioembolization,not specified,"progression-free survival, time to progression, objective response rate, overall survival","open-label, single-arm multicenter pilot study",False,"Population and intervention match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
112,not specified,not specified,not specified,relationship between gut microbiota and gastrointestinal disorders,observational research using Mendelian randomization,False,Does not match any of the target PICOS criteria.
113,patients with unresectable hepatocellular carcinoma,sintilimab plus IBI305 and HAIC,not specified,"objective response rate, overall survival, event-free survival",clinical trial,False,"Population and intervention match, but no comparison to standard therapy or placebo, and study design is not specified as a randomized controlled trial."
114,patients with initially unresectable hepatocellular carcinoma,lenvatinib combined with TACE plus PD-1 inhibitor,initial surgery,"event-free survival, overall survival",retrospective study with propensity score matching,False,"Population and intervention match, comparison is to initial surgery not standard therapy or placebo, and study design is not a randomized controlled trial."
115,Chinese young adults at risk of NAFLD,"educational interventions (pamphlet, video)",no intervention,awareness and knowledge of NAFLD,randomized controlled trial,False,"Population does not match, intervention is not immunotherapy or targeted therapy, and outcomes are not survival or response rate."
116,postmenopausal women,dietary patterns,not specified,"incident liver cancer, chronic liver disease mortality",prospective cohort analysis,False,"Population does not match, intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
117,HCC patients with negative AFP and PIVKA-II,not specified,HCC patients with at least 1 positive AFP or PIVKA-II,risk factors for AFP and PIVKA-II negativity,retrospective study,False,"Population partially matches, but intervention is not specified, and study design is not a randomized controlled trial."
118,systemic treatment-naive patients with unresectable hepatocellular carcinoma,tislelizumab plus lenvatinib,not specified,"objective response rate, disease control rate, progression-free survival, overall survival","multicenter, single-arm, phase 2 study",False,"Population and intervention match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
119,patients with hepatocellular carcinoma undergoing LDLT,not specified,not specified,"disease-free survival, overall survival",retrospective observational single-center study,False,"Population partially matches, but intervention is not specified, and study design is not a randomized controlled trial."
90,patients with cirrhosis,hepatocellular carcinoma screening outreach,not specified,financial harms and burden,multicenter pragmatic randomized clinical trial,False,Population does not specifically target hepatocellular carcinoma patients. Intervention and outcomes do not match the target criteria.
91,patients with oligometastatic hepatocellular carcinoma,stereotactic ablative radiotherapy (SABR),not specified,"overall survival, progression-free survival, local progression, objective response rate, disease control rate, toxicities, quality of life",prospective study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, and there is no comparison to standard therapy or placebo."
92,patients with HBV-positive recurrent HCC post-liver transplant,mRNA electroporated HBV-specific TCR T cells,not specified,"safety, tolerability, anti-tumor efficacy",phase I clinical trial,False,"Population matches, but intervention is not standard immunotherapy or targeted therapy, and there is no comparison to standard therapy or placebo."
93,HCC patients undergoing hepatectomies,not specified,HCC patients with or without autoimmune diseases,"overall survival, liver-specific survival, disease-free survival",retrospective study,False,"Population matches, but intervention is not specified, and study design is not a randomized controlled trial."
94,people with NASH and type 2 diabetes,MPC inhibitor MSDC-0602K,placebo,"BCAA concentrations, BCKDH phosphorylation","randomized, placebo-controlled Phase IIB clinical trial",False,"Population does not match, and outcomes are not related to survival or response rate in hepatocellular carcinoma."
95,patients with advanced stage HCC,"lenvatinib, sintilimab plus TACE",not specified,"progression-free survival, overall survival, objective response rate, disease control rate",single-arm phase II trial,False,"Population and intervention match, but there is no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
96,BCLC-C hepatocellular carcinoma patients,palliative stereotactic body radiation therapy (SBRT),not specified,"local control, overall survival, adverse events",observational retrospective study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
97,patients with advanced ESCC and HCC,AL2846 (TKI) with anti-PD-L1 antibody (TQB2450),not specified,"overall response rate, progression-free survival, overall survival, disease control rate",phase 1b study,False,"Population matches, but intervention is not standard immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
98,patients with multifocal stage 2 HCC,liver transplantation or partial hepatectomy,liver transplantation vs. partial hepatectomy,overall survival,propensity score-based observational study,False,"Population matches, but interventions are surgical and not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
99,patients with untreated advanced HCC,anlotinib alone or combined with S-1,anlotinib vs. anlotinib+S-1,"objective response rate, disease control rate, progression-free survival, overall survival",randomized study,False,"Population matches, but intervention is not standard immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
150,patients with HCC recurrence post-surgery,sequential therapy with ropeginterferon alfa-2b and nivolumab,not specified,"safety, tolerability, and inhibitory activity",Phase I clinical trial,False,"Population and intervention match, but no comparison to standard therapy or placebo, and outcomes do not include survival or response rate."
151,HBV-related HCC patients post-surgery,TDF switch therapy,ETV maintenance,3-year recurrence free survival and overall survival,"randomized, open-label, phase III trial",True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design."
152,"patients with advanced solid tumors, including HCC",SAR'459 ± cemiplimab,not specified,"safety, pharmacokinetics, pharmacodynamics, and antitumor activity",phase I/Ib study,False,Population includes HCC but not exclusively; no comparison to standard therapy or placebo; outcomes do not include survival or response rate.
153,patients with advanced HCC,doxorubicin plus sorafenib vs. sorafenib,sorafenib,overall survival and progression-free survival,randomized phase III trial,True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design."
154,HCC patients undergoing hepatectomy,prophylactic dexamethasone,control group,perioperative outcomes,randomized controlled trial,False,"Population and study design match, but intervention is not immunotherapy or targeted therapy, and outcomes do not include survival or response rate."
155,HCC patients post-narrow-margin hepatectomy,radiotherapy vs. TACE,TACE,overall survival and progression-free survival,prospective randomized study,False,"Population and outcomes match, but interventions are not immunotherapy or targeted therapy."
156,inpatients with cirrhosis,not specified,not specified,death and receipt of liver transplant,prospective observational cohort study,False,Population does not specifically include HCC patients; no intervention or comparison specified.
157,MVI-negative HCC patients,Gd-EOB-DTPA MRI,not specified,recurrence-free survival,retrospective study,False,"Population matches, but intervention is diagnostic, not therapeutic, and no comparison to standard therapy or placebo."
158,postoperative liver cancer patients,Home to Hospital to Home nutrition management program,general nutritional method,nutrition-related indicators and complications,randomized controlled trial,False,"Population includes liver cancer but not specifically HCC; intervention is nutritional, not immunotherapy or targeted therapy."
159,patients with unresectable HCC,atezolizumab plus bevacizumab,not specified,progression-free survival and overall survival,prospective observational study,False,"Population and intervention match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
140,patients with unresectable hepatocellular carcinoma,DEB-TACE with doxorubicin-loaded CalliSpheres microspheres,cTACE with doxorubicin-lipiodol emulsion,"clinical response rate, overall survival, progression-free survival",randomized controlled trial,True,"Matches all PICOS criteria: population with HCC, intervention and comparison are specified, outcomes include survival and response rate, study design is RCT."
141,patients with HCC and Vp4 PVTT,irradiation stent placement plus TACE,sorafenib plus TACE,"overall survival, hepatic function, time to symptomatic progression",multicenter randomized controlled trial,True,"Matches all PICOS criteria: population with HCC, intervention and comparison are specified, outcomes include survival, study design is RCT."
142,HCC patients with high relapse risks after surgery,postoperative adjuvant anti-PD-1 antibody,no PD-1 treatment after hepatectomy,"overall survival, recurrence-free survival",prospective observational study,False,Does not match study design criteria: not an RCT.
143,CHB patients with intermediate to high risk of HCC,IFN add-on NAs therapy,NAs monotherapy,"HCC incidence, HBsAg loss",multi-center randomized controlled trial,False,"Population does not match: patients are with CHB, not HCC."
144,patients with suspected malignant liver lesions,[(18)F]FAPI-04 PET/CT scanning,[(18)F]FDG PET/CT scanning,"sensitivity, specificity, accuracy of each tracer",not specified,False,Population and outcomes do not match: not focused on HCC patients or survival/response rate.
145,elderly patients with unresectable HCC,sorafenib or lenvatinib,not specified,"progression-free survival, overall survival",retrospective observational study,False,Does not match study design criteria: not an RCT.
146,patients with HCC or metastatic colorectal cancer,SIRT with (90)Y resin microspheres,not specified,"overall response rate, overall survival","multicenter, single-arm, prospective, observational study",False,Does not match study design criteria: not an RCT.
147,patients with early-stage HCC,machine learning model for treatment recommendations,not specified,survival rates,not specified,False,"Intervention and study design do not match: not focused on immunotherapy or targeted therapy, not an RCT."
148,patients who achieved HBsAg seroclearance following peg-IFN-α-based treatments,peg-IFN-α-based therapy,not specified,HBsAg recurrence,"prospective, multicenter, observational study",False,Population and outcomes do not match: not focused on HCC patients or survival/response rate.
149,patients with impaired liver function or tumors not amenable to thermal ablation,SBRT with dose optimization,conventional SBRT,"local control, toxicity",phase II clinical trial,False,Population and outcomes do not match: not focused on HCC patients or survival/response rate.
160,"patients with single huge, resectable hepatocellular carcinoma","neoadjuvant therapy with TACE, camrelizumab, and apatinib",surgery alone,recurrence-free survival at 1 year,"multi-center, open-label randomized phase 3 trial",True,matches all target PICOS criteria
161,patients with hepatocellular carcinoma eligible for TACE,TACE-DEB,SBRT,"time to progression, local control, overall survival, response rate",multicenter randomized trial,False,intervention and comparison do not match target criteria
162,patients with HBV-related HCC within Milan criteria and clinically significant PHT,partial hepatectomy,interventional treatment using ablation with or without pre-ablation TACE,"overall survival, recurrence-free survival",open-label randomized clinical trial,False,intervention and comparison do not match target criteria
163,cancer patients with chronic hepatitis B undergoing chemotherapy,24-week vs. 48-week TDF prophylaxis,not specified,cumulative incidence of virological and clinical relapse,"phase IV, prospective randomized trial",False,population and intervention do not match target criteria
164,treatment-naive patients with advanced hepatocellular carcinoma,toripalimab plus bevacizumab,not specified,"objective response rate, progression-free survival, overall survival","phase II, multicenter, prospective, single-arm study",False,comparison and study design do not match target criteria
165,patients with resectable single and small hepatitis B virus-related HCC predicted to have high risks of MVI,neoadjuvant intensity modulated radiation therapy,upfront surgery,"disease-free survival, overall survival",randomized trial,False,intervention does not match target criteria
166,CHB patients with histologically confirmed advanced liver fibrosis/early cirrhosis,ETV plus RG,ETV alone,"fibrosis regression, inflammation remission, risk of HCC",randomized and blindly allocated trial,False,population and intervention do not match target criteria
167,HCC patients who underwent hepatectomy,postoperative adjuvant transarterial chemoembolization,no PA-TACE,"disease-free survival, overall survival",retrospective analysis,False,study design does not match target criteria
168,patients with advanced solid tumors and BRCA1/2 mutations,talazoparib,not specified,"disease control, objective response, progression-free survival, overall survival",phase II basket trial,False,population and intervention do not match target criteria
169,individuals at high risk for hepatocellular carcinoma,mHealth-based intervention program,usual health education,"knowledge of LC prevention, screening intentions","two-arm, single-blind randomized controlled trial",False,population and intervention do not match target criteria
180,patients with cirrhosis and chronic hepatitis B,telehealth consultations,standard consultations,HCC surveillance uptake,retrospective observational study,False,"Population does not specifically mention hepatocellular carcinoma, intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
181,patients with NAFLD,probiotic supplementation,standard treatment,NAFLD fibrosis score,randomized controlled trial,False,"Population is not specifically patients with hepatocellular carcinoma, and intervention is not immunotherapy or targeted therapy."
182,compensated cirrhosis patients with LS≥25 kPa,carvedilol therapy,placebo,incidences of decompensated events and liver-related death,"randomized, double-blind, placebo-controlled trial",False,"Population is not specifically patients with hepatocellular carcinoma, and intervention is not immunotherapy or targeted therapy."
183,patients with hepatocellular carcinoma,laparoscopic major hepatectomy,open major hepatectomy,2-year recurrence-free survival,randomized trial,False,"Intervention is surgical, not immunotherapy or targeted therapy."
184,patients with metastatic NSCLC,new systemic treatments,control arm,"QoL, PFS, and OS",randomized controlled trials,False,Population is not patients with hepatocellular carcinoma.
185,patients with HCC and cirrhosis,not specified,not specified,rehabilitation nursing impact,not specified,False,"Intervention, comparison, and study design are not specified, and the focus is not on survival or response rate."
186,patients with liver cirrhosis,state-of-the-art tests for early HCC detection,not specified,early HCC detection,"prospective, longitudinal, diagnostic, prognostic study",False,"Population is not specifically patients with hepatocellular carcinoma, and intervention is not immunotherapy or targeted therapy."
187,patients with CHB-associated liver fibrosis,hydronidone plus entecavir,placebo plus entecavir,fibrosis improvement,"randomized, double-blind, placebo-controlled trial",False,"Population is not specifically patients with hepatocellular carcinoma, and intervention is not immunotherapy or targeted therapy."
188,patients with HCC treated with TACE,CEUS Nonradiation TRA LI-RADS,not specified,diagnostic performance for viable tumors,retrospective observational study,False,"Intervention is diagnostic, not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
189,patients with liver tumours,TARE with Yttrium-90 resin microspheres,not specified,adverse events,prospective observational study,False,"Population is not specifically patients with hepatocellular carcinoma, and study design is not a randomized controlled trial."
210,chickens infected with Salmonella enterica,puerarin treatment,control group and S. enterica group,"liver metabolism, inflammation, oxidative damage, and hepatocellular carcinoma biomarkers",randomized controlled trial,False,Population does not match (not hepatocellular carcinoma patients).
211,patients with acromegaly,not specified,patients without acromegaly,cancer incidence,"observational, retrospective study",False,Population and intervention do not match the target criteria.
212,obese cirrhotic patients with and without HCC,spectroscopic methods,not specified,diagnostic accuracy for HCC,not specified,False,Intervention and comparison do not match the target criteria.
213,cirrhotic patients with non-symptomatic portal vein thrombosis,warfarin anticoagulation therapy,untreated group,"recanalization probability, bleeding events, mortality, ascites aggravation",randomized controlled trial,False,Population does not match (not hepatocellular carcinoma patients).
214,patients with asymptomatic synchronous unresectable colorectal liver-limited metastases,pre-PTR chemotherapy,upfront PTR,"progression-free survival, overall survival, tumour response, disease control rate, liver metastases resection rate, surgical complications, chemotherapy toxicity",randomized controlled trial,False,Population does not match (not hepatocellular carcinoma patients).
215,liver cancer patients undergoing laparoscopic hepatectomy,continuous lidocaine infusion,not specified,pharmacokinetics characteristics and safety,not specified,False,Intervention and comparison do not match the target criteria.
216,liver kidney transplant recipients,not specified,not specified,"prevalence of incidental HCC or iCC, patient, kidney, and liver graft survival","observational, retrospective study",False,Population and intervention do not match the target criteria.
217,patients with chronic liver disease in Sweden,not specified,not specified,"incidence, prevalence, and mortality","register-based, nationwide observational study",False,Population and intervention do not match the target criteria.
218,"population in Ma'anshan, China",not specified,not specified,cancer incidence and trends,not specified,False,Population and intervention do not match the target criteria.
219,COVID-19 patients with chronic liver diseases,not specified,not specified,risk factors for unfavourable outcome,retrospective observational study,False,Population and intervention do not match the target criteria.
170,HCV-infected patients with hepatocellular carcinoma,sofosbuvir/velpatasvir or glecaprevir/pibrentasvir,not specified,sustained virological response and safety,observational study,False,"Population and intervention partially match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
171,patients with HCC of BCLC stage A exceeding the Milan criteria or BCLC stage B,sintilimab plus DEB-TACE,not specified,"progression-free survival, objective response rate, pathologic response rate, and safety","prospective, phase II study",False,"Population and intervention match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
172,HCC patients with PVTT,DEB-TACE,cTACE,"progression-free survival, overall survival, and incidence of adverse events",randomized controlled trial,True,"Population, intervention, comparison, outcome, and study design all match the target criteria."
173,patients with recurrent HCC and preoperative CTC data,not specified,not specified,extrahepatic recurrence prediction,not specified,False,"Population matches, but intervention, comparison, outcome, and study design do not match the target criteria."
174,patients undergoing elective LLR,low pneumoperitoneal pressure,standard pneumoperitoneal pressure,occurrence of gas embolism,randomized controlled trial,False,"Population, intervention, comparison, and study design match, but outcome does not match the target criteria."
175,patients with a single HCC ≤5 cm,CEUS and EOB-MRI,not specified,MVI prediction,not specified,False,"Population matches, but intervention, comparison, outcome, and study design do not match the target criteria."
176,HCV patients without decompensated cirrhosis or liver cancer,sofosbuvir + ribavirin or sofosbuvir + ledipasvir,not specified,sustained virological response at 12 weeks after end of treatment,multi-country open-label trial,False,"Population and intervention partially match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
177,adults with alopecia areata,ritlecitinib,placebo,BAEP changes and IENF histology,"phase 2a, double-blind study",False,"Population does not match, and outcome does not match the target criteria."
178,patients with refractory MSS CLM,VB-111 and nivolumab,not specified,overall response rate and safety/tolerability,phase II study,False,"Population and intervention match, but no comparison to standard therapy or placebo, and study design is not a randomized controlled trial."
179,patients with previously treated unresectable HCC,local ablation plus PD-1 inhibitor toripalimab,toripalimab alone,progression-free survival and overall survival,"multicenter, two-stage, and randomized phase 1/2 trial",True,"Population, intervention, comparison, outcome, and study design all match the target criteria."
200,patients undergoing major hepatectomy,arterial lactate measurements,clinical risk factors and bilirubin POD1,predicting post-hepatectomy liver failure,observational cohort study,False,Population does not match; intervention and comparison not related to immunotherapy or targeted therapy; study design not RCT
201,HCC patients undergoing liver resection,von Willebrand factor antigen as a biomarker,not specified,time to recurrence and overall survival,prospective trial,False,Population matches; intervention not related to immunotherapy or targeted therapy; study design not RCT
202,chronic hepatitis B patients with antiviral therapy,Entecavir treatment,not specified,"fibrosis reversal, HCC and decompensated cirrhosis incidence","multicenter, center-randomized, double-blind clinical trial",False,Population does not match; intervention not related to immunotherapy or targeted therapy; study design not RCT
203,adults diagnosed with HCC,not specified,not specified,"HCC incidence, stage at diagnosis, and survival",observational study,False,Population matches; intervention not specified; study design not RCT
204,unresectable HCC patients,TACE followed by SBRT,TACE alone,"local control, progression free survival, overall survival",randomized controlled trial,False,Population matches; intervention not related to immunotherapy or targeted therapy; study design matches
205,patients with cHCC-CCA,surgical resection or liver transplant,not specified,recurrence-free survival and overall survival,retrospective observational study,False,Population does not match; intervention not related to immunotherapy or targeted therapy; study design not RCT
206,"patients with advanced solid tumors, RCC, CCA, or HCC",TPST-1120 monotherapy or in combination with nivolumab,not specified,"safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity","phase I, open-label, dose-escalation study",True,Population matches; intervention includes targeted therapy; study design is a clinical trial but not explicitly RCT
207,patients with primary liver cancer,precision hepatectomy,conventional hepatectomy,"surgical condition, complications, liver function, immune function, recurrence rate, mortality rate",randomized controlled trial,False,Population matches; intervention not related to immunotherapy or targeted therapy; study design matches
208,intermediate-stage HCC patients,pembrolizumab following TACE,not specified,safety and bioactivity,phase Ib study,True,Population matches; intervention includes immunotherapy; study design is a clinical trial but not explicitly RCT
209,patients with surgically unresectable HCC,resin 90 Y radioembolization,not specified,"overall survival, progression-free survival, and local duration of response","prospective, single-center, single-arm clinical trial",False,Population matches; intervention not related to immunotherapy or targeted therapy; study design not RCT
230,patients with primary clear cell carcinoma of the liver and common hepatocellular carcinoma,Faster RCNN model for differential diagnosis,not specified,"accuracy, average precision, and recall of the model",not specified,False,"Population includes non-target condition (PCCCL), intervention is diagnostic not therapeutic, no comparison or study design specified."
231,"adults with untreated, unresectable/metastatic HCC","BMS-986,205 in combination with nivolumab",not specified,"safety, tolerability, and preliminary efficacy",Phase I/II study,False,"Population matches, intervention is targeted therapy, but no comparison to standard therapy or placebo, and outcomes do not include survival or response rate."
232,patients with liver cancer after TACE,individualized nutritional intervention,routine dietary intervention,"nutritional status, liver function status, and incidence of complications",randomized controlled trial,False,"Population is broader than hepatocellular carcinoma, intervention is not immunotherapy or targeted therapy, outcomes do not include survival or response rate."
233,HCC patients,outpatient palliative care intervention,usual care,quality of life and symptom burden,randomized controlled trial,False,"Population matches, but intervention is not immunotherapy or targeted therapy, outcomes do not include survival or response rate."
234,HCV-monoinfected patients with F3 fibrosis,not specified,not specified,development of HCC,observational and retrospective study,False,"Population does not specifically have hepatocellular carcinoma, no intervention or comparison specified, study design is not a randomized controlled trial."
235,hepatocellular carcinoma patients,real-time image-guided radiation therapy using x-ray images,not specified,feasibility of using x-ray images for real-time tracking,observational study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, no comparison specified, study design is not a randomized controlled trial."
236,general population without prior liver diseases,not specified,not specified,"presence of NAFLD, severe NAFLD, and severe liver diseases",observational and Mendelian randomization study,False,"Population does not have hepatocellular carcinoma, no intervention or comparison specified, study design is not a randomized controlled trial."
237,patients undergoing curative intended liver resection of hepatic primary or secondary malignancies,not specified,not specified,"postoperative outcomes including complications, lengths of hospital stay, and mortality",observational study,False,"Population includes non-target conditions, no intervention or comparison specified, study design is not a randomized controlled trial."
238,patients with HCC after curative resection,preoperative contrast-enhanced ultrasound,not specified,early recurrence of HCC,not specified,False,"Population matches, but intervention is diagnostic not therapeutic, no comparison or study design specified."
239,individuals referred for liver CT scans,low-dose CT with deep learning-based denoising,standard-dose CT with model-based iterative reconstruction,image quality and diagnostic capability in detecting malignant liver tumors,"prospective, multicenter, noninferiority study",False,"Population is broader than hepatocellular carcinoma, intervention is diagnostic not therapeutic, outcomes do not include survival or response rate."
190,patients with unresectable hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,progression-free survival and overall survival,randomized controlled trial,True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design align with target criteria."
191,patients at high risk for HCC,semi-annual US and AMRI,semi-annual US alone,cost/quality-adjusted life year and cost/patient detected with a BCLC 0 HCC,randomized controlled trial,False,Population and outcome do not match target criteria; focuses on screening rather than treatment outcomes.
192,adult patients with cirrhosis or advanced fibrosis,mailed letter with a signed order for an ultrasound,usual care,completion of ultrasound within 6 months,randomized controlled trial,False,Population and outcome do not match target criteria; focuses on surveillance uptake rather than treatment outcomes.
193,patients with chronic hepatitis B and biopsy-proven histological significant fibrosis,entecavir-based therapy,not specified,7-year cumulative incidence of HCC,randomized controlled trial,False,Population and intervention do not match target criteria; focuses on hepatitis B rather than hepatocellular carcinoma.
194,HR+/Her2- locally advanced breast cancer patients,DEB-TACE combined with the TAC regimen,TAC regimen intravenously,"overall response rate, pathological complete response",controlled study,False,Population does not match target criteria; focuses on breast cancer rather than hepatocellular carcinoma.
195,patients with unresectable hepatocellular carcinoma,DEB-TACE combined with apatinib,DEB-TACE monotherapy,"progression-free survival, overall survival, objective response rates, disease control rates",randomized controlled trial,True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design align with target criteria."
196,BCLC early stage HCC patients with lesions 2-5 cm,(super-)selective infusion of (166)Ho-MS after RFA,not specified,target volume dose of ≥ 120 Gy,"multicenter, prospective dose-escalation study",False,Study design and comparison do not match target criteria; not a randomized controlled trial and lacks a standard therapy or placebo comparison.
197,patients with unresectable HCC,selective internal radiation therapy,not specified,"downstaging achieved, overall survival","retrospective, observational study",False,Study design and comparison do not match target criteria; not a randomized controlled trial and lacks a standard therapy or placebo comparison.
198,"patients with pancreatic, biliary tract, and liver cancer",blood-flow restricted resistance training,control group,skeletal muscle thickness and muscle cross-sectional area,randomized controlled trial,False,Population and outcome do not match target criteria; focuses on muscle mass and function rather than survival or response rate.
199,patients with advanced chemo-refractory proficient mismatch repair or microsatellite stable gastrointestinal malignancies,cabozantinib plus durvalumab,not specified,"objective response rate, disease control rate, progression-free survival, overall survival",phase Ib part of the phase I/II trial,False,Population and study design do not match target criteria; includes various gastrointestinal malignancies and not a randomized controlled trial.
220,children and adolescents with non-alcoholic fatty liver disease,Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter,not specified,prevalence of significant liver fibrosis and non-alcoholic fatty liver disease,cross-sectional population-based study,False,Population does not match; intervention and comparison do not match target criteria; study design is not a randomized controlled trial.
221,patients with HBV-related hepatocellular carcinoma,not specified,not specified,overall survival,multicenter study with nomogram construction and validation,False,Intervention and comparison not specified; study design does not match target criteria.
222,HCV patients with hepatocellular carcinoma,direct-acting antivirals after tumor ablation,postponed DAAs initiation for 12 months,1-year HCC recurrence rates,randomized controlled trial,True,"Population, intervention, comparison, outcome, and study design match target criteria."
223,patients with hepatocellular carcinoma undergoing TACE,preoperative interview and prospective nursing,routine nursing care,"postoperative pain, satisfaction levels, and incidence of complications",randomized controlled trial,False,Intervention does not match target criteria; outcome does not match target criteria.
224,"Nigerian adults with hepatocellular carcinoma, with and without HIV",not specified,not specified,survival,prospective observational study,False,Intervention and comparison not specified; study design does not match target criteria.
225,patients scheduled for bariatric surgery with NAFLD/NASH,bariatric surgery,not specified,change of steatosis and liver fibrosis 5 years after surgery,observational prospective cohort study,False,Population does not match; intervention and comparison do not match target criteria; study design does not match target criteria.
226,patients with decompensated liver cirrhosis,human umbilical cord blood-derived mesenchymal stem cell transplantation,not specified,"overall survival, 3-year and 5-year survival rates, occurrence rate of HCC",retrospective cohort study,False,Population does not match; intervention and comparison do not match target criteria; study design does not match target criteria.
227,patients with hepatocellular carcinoma ineligible for surgery due to insufficiency of the future liver remnant,holmium-166 unilobar radioembolization,not specified,"safety and toxicity profile, dose-response relationships, feasibility of surgical resection, quality of life","multicenter, interventional, non-randomized, open-label, non-comparative safety study",False,Intervention and comparison do not match target criteria; study design does not match target criteria.
228,patients with HCC treated with sorafenib or SIRT and sorafenib,not specified,not specified,overall survival,"exploratory subanalysis of a prospective, randomized controlled trial",False,Intervention and comparison not specified; study design does not match target criteria.
229,patients with unresectable hepatocellular carcinoma,bevacizumab and atezolizumab,not specified,"response rate, disease control rate, progression-free survival, overall survival",not specified,False,Comparison not specified; study design not specified; intervention partially matches target criteria.
240,patients with chronic liver disease,not specified,not specified,overall survival,retrospective observational study,False,Population does not match; study design is not a randomized controlled trial.
241,patients with liver cancer undergoing TACE,modular multimodal hospital-home chain physical activity rehabilitation programme,standard care,"liver frailty index, quality of life, fatigue, sleep quality, anxiety, depression, physical activity level",randomized controlled trial,False,Population and intervention do not match the target criteria.
242,patients with small malignant liver tumors,CEUS-CT/MRI fusion imaging,B-mode US,"tumor visibility, technical success, technique efficacy, local tumor progression, major complications",prospective study,False,Population and intervention do not match the target criteria; study design is not a randomized controlled trial.
243,cancer patients in Pakistan,not specified,not specified,cancer types and frequencies,observational study,False,"Population, intervention, and study design do not match the target criteria."
244,patients with unresectable hepatocellular carcinoma,apatinib combined with intensity-modulated radiation therapy,not specified,"progression-free survival, overall survival, disease control rate, objective response rate, safety","open-label, single-arm, exploratory clinical trial",False,Study design is not a randomized controlled trial; no comparison group specified.
245,patients with focal liver lesions,super-resolution ultrasound imaging,not specified,microvasculature visualization and quantification,prospective study,False,Population and intervention do not match the target criteria; study design is not a randomized controlled trial.
246,treatment-naive HBV-related decompensated cirrhosis patients,antiviral treatment,not specified,"recompensation rate, second decompensation rate, long-term prognosis",retrospective multi-center study,False,Population and study design do not match the target criteria.
247,HCC patients with AFP or PIVKA-II positivity,curative-intent resection,serological complete conversion vs. serological incomplete conversion,"recurrence, overall survival",multicenter observational study,False,Population and study design do not match the target criteria.
248,HCC patients beyond the Milan criteria treated by TACE after TIPS,transarterial chemoembolization,not specified,overall survival,retrospective study,False,Population and study design do not match the target criteria.
249,Asian Americans with chronic hepatitis B,Patient Navigator-led Intervention,control group,"rates of doctor visits, ALT testing",randomized controlled trial,False,Population and intervention do not match the target criteria.
260,patients with unresectable hepatocellular carcinoma,transarterial chemoembolization combined with programmed cell death protein-1 inhibitors plus lenvatinib,programmed cell death protein-1 inhibitors plus lenvatinib,"objective response rate, overall survival, progression-free survival","observational, retrospective, cohort study",False,Study design is not a randomized controlled trial.
261,patients with advanced digestive tract cancer including hepatocellular carcinoma,PD-1 inhibitors plus antiangiogenic agents,not specified,"objective response rate, progression-free survival, overall survival",observational retrospective study,False,Study design is not a randomized controlled trial and comparison is not specified.
262,patients diagnosed with combined hepatocellular-cholangiocarcinoma,not specified,not specified,early postoperative recurrence,retrospective study,False,"Intervention and comparison not specified, study design is not a randomized controlled trial."
263,sorafenib-experienced patients with hepatocellular carcinoma,nivolumab plus ipilimumab,not specified,"objective tumor response, overall survival","open-label, multicohort, phase I/II trial",False,"Comparison not specified, study design is not a randomized controlled trial."
264,patients with high-risk recurrence factors after curative resection of hepatocellular carcinoma,Cidan Capsule combined with adjuvant transarterial chemoembolization,adjuvant transarterial chemoembolization,"disease-free survival, tumor recurrence rate, overall survival","multicenter, randomized controlled trial",True,Matches all PICOS criteria.
265,patients with advanced hepatocellular carcinoma,GT90001 plus nivolumab,not specified,"objective response rate, progression-free survival",phase 1b/2 study,False,"Comparison not specified, study design is not a randomized controlled trial."
266,individuals with chronic hepatitis C,INO-8000 with or without INO-9012,not specified,HCV-specific CD4+ and CD8+ T-cell immune responses,"phase I, multisite dose-escalation trial",False,"Population and outcomes do not match, study design is not a randomized controlled trial."
267,patients with unresectable hepatocellular carcinoma,DEB-TACE with CalliSpheres microspheres,conventional transarterial chemoembolization,"objective response rate, overall survival, progression-free survival",not specified,False,Study design not specified.
268,patients with non-alcoholic fatty liver disease,high-intensity interval training and iranian propolis extract,not specified,serum levels of TRPV4 and CYP2E1 proteins,randomized control trial,False,Population and outcomes do not match.
269,patients with hepatocellular carcinoma following initial curative-intent resection or ablation,not specified,not specified,overall survival,retrospective observational study,False,"Intervention and comparison not specified, study design is not a randomized controlled trial."
290,patients with HCC,IDA-TACE,DOX-TACE,objective response rate,randomized controlled trial,False,Intervention is not immunotherapy or targeted therapy
291,patients with PBC,serum ATX levels,not specified,liver-related events,retrospective multicenter investigation,False,Population and intervention do not match criteria
292,patients with advanced/metastatic solid tumors,CS1002 and CS1003,not specified,objective responses,phase 1 study,False,Population and study design do not match criteria
293,patients with liver tumors,ICG fluorescence imaging,not specified,resection margin determination,"prospective, single-center, non-randomized controlled study",False,Population and intervention do not match criteria
294,patients with advanced or metastatic HCC,itacitinib,not specified,safety and efficacy,Phase Ib study,False,Study design does not match criteria
295,patients with low PLT counts undergoing RFA for liver tumors,Lusutrombopag,not specified,PLT count elevation,not specified,False,Population and intervention do not match criteria
296,patients with and without FLLs,AI system for ultrasound,not specified,FLL detection rate,single-center prospective randomized controlled study,False,Population and intervention do not match criteria
297,patients with cirrhosis undergoing invasive procedures,ROTEM-based algorithm,standard of care,procedure-related bleeding complications,multi-centre randomised controlled trial,False,Population and intervention do not match criteria
298,HCC patients,nomogram based on HCC-GRIm score,not specified,prognosis prediction,not specified,False,Intervention and study design do not match criteria
299,HCC patients with IVCTT,SBRT,not specified,local control and overall survival,observational retrospective study,False,Study design does not match criteria
270,patients with unresectable hepatocellular carcinoma,anlotinib combined with toripalimab,not specified,"objective response rate, disease control rate, progression-free survival, overall survival","single-arm, multicenter, phase II study",False,No comparison group specified and not a randomized controlled trial.
271,patients with unresectable hepatocellular carcinoma,transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab,not specified,"progression-free survival, objective response rate",not specified,False,No comparison group specified and study design not specified as randomized controlled trial.
272,patients with unresectable hepatocellular carcinoma previously treated with systemic therapy,atezolizumab and bevacizumab,not specified,"overall survival, time-to-progression, progression-free survival, objective response rate","global, multicenter, observational study",False,No comparison group specified and not a randomized controlled trial.
273,patients with PTEN-deficient advanced intrahepatic cholangiocarcinoma,bortezomib,not specified,"objective response rate, disease control rate, progress-free survival, overall survival",phase II trial,False,"Population does not match, no comparison group specified, and not a randomized controlled trial."
274,patients with hepatocellular carcinoma,alcohol consumption,glycemic status,HCC incidence,population-based observational cohort study,False,"Intervention and outcome do not match, and not a randomized controlled trial."
275,patients scheduled to undergo laparoscopic hepatectomy due to hepatocellular carcinoma,bilateral posterior quadratus lumborum block with ropivacaine,0.9% saline,"cumulative opioid consumption, pain scores","prospective, double blinded, randomized controlled trial",False,Population and intervention do not match the target criteria.
276,hepatocellular carcinoma patients receiving sorafenib or lenvatinib,telephone follow-up,no telephone follow-up,"incidence of adverse events, adherence to oral chemotherapy, disease control rate","single-center, observational, retrospective study",False,Intervention and study design do not match the target criteria.
277,patients with hepatocellular carcinoma undergoing resin-based Y90 radioembolization,prospective voxel-based dosimetry,not specified,"treatment response, adverse events",prospective single-arm clinical trial,False,No comparison group specified and not a randomized controlled trial.
278,patients treated with sorafenib for advanced hepatocellular carcinoma,sorafenib,not specified,"overall survival, time to radiological and symptomatic progression",retrospective review,False,No comparison group specified and not a randomized controlled trial.
279,adult patients undergoing orthotopic liver transplantation,Bicarbonate Ringer's solution,Acetate Ringer's solution,"pH and base excess levels, incidence and volume of intraoperative 5% sodium bicarbonate infusion, liver and kidney function",not specified,False,Population and intervention do not match the target criteria.
300,patients with hepatocellular carcinoma,thermal ablation,not specified,recurrence-free survival,observational study,False,Intervention and study design do not match target criteria.
301,patients with advanced biliary tract cancer,atezolizumab with or without bevacizumab,placebo,overall survival,randomized controlled trial,False,Population does not match target criteria.
302,patients with intermediate-stage hepatocellular carcinoma,lenvatinib and transcatheter arterial chemoembolisation,not specified,"resection rate, overall survival","single-arm, prospective clinical trial",False,Comparison and study design do not match target criteria.
303,patients with standard chemotherapy refractory mismatch repair proficient metastatic colorectal cancer,pexastimogene devacirepvec plus durvalumab with and without tremelimumab,not specified,"progression-free survival, overall survival",phase I/II trial,False,Population and study design do not match target criteria.
304,hepatitis B surface antigen-positive adults,anti-HBV therapy,not specified,"HBV treatment initiation, major adverse liver outcomes",multicenter longitudinal cohort study,False,Population and intervention do not match target criteria.
305,patients with hepatocellular carcinoma resistance to lenvatinib,lenvatinib plus gefitinib,not specified,"progression-free survival, overall survival","single-arm, open-label, exploratory study",False,Comparison and study design do not match target criteria.
306,chronic hepatitis C patients who achieved SVR with SOF-based treatment,sofosbuvir or ledipasvir/sofosbuvir,not specified,HCC occurrence,"prospective, multicenter observational study",False,Population and intervention do not match target criteria.
307,patients undergoing routine ERCP procedures,endoscopic optical light scattering technique,not specified,detection of malignant transformation,pilot in vivo double-blind prospective study,False,Population and intervention do not match target criteria.
308,hepatocellular carcinoma patients,transvascular antitumor interventional therapy,not specified,"disease control rate, progression-free survival",single-center observational case-control study,False,Intervention and study design do not match target criteria.
309,chronic hepatitis C patients who reached SVR after DAA treatment,direct-acting antivirals,not specified,"long-term prognosis, clinical outcomes","single-center, retrospective, observational study",False,Population and intervention do not match target criteria.
310,patients with advanced unresectable hepatocellular carcinoma,transarterial radioembolization,standard therapy,survival outcomes,randomized controlled trial simulation,False,"Intervention is not immunotherapy or targeted therapy, and study design is a simulation, not a direct RCT."
311,patients with NAFLD,not specified,not specified,prevalence of hepatocellular carcinoma,retrospective study,False,"Population does not specifically have hepatocellular carcinoma, and study design is not an RCT."
312,patients with metastatic colorectal cancer to the liver,transarterial chemoembolization with HepaSphere Microspheres,not specified,"overall survival, progression-free survival",prospective study,False,"Population does not have hepatocellular carcinoma, and study design is not an RCT."
313,patients with hepatocellular carcinoma smaller than 2 cm,surgical resection,not specified,"recurrence-free survival, overall survival",retrospective observational study,False,"Intervention is not immunotherapy or targeted therapy, and study design is not an RCT."
314,patients with cirrhosis and hepatocellular carcinoma,abstinence from alcohol,non-alcohol-related cirrhosis,"access to curative treatment, 5-year survival",prospective study,False,"Intervention is not immunotherapy or targeted therapy, and study design is not an RCT."
315,patients with hepatocellular carcinoma,decision support intervention,control group,"treatment knowledge, decisional conflict",randomized controlled trial,False,Intervention is not immunotherapy or targeted therapy.
316,patients with chronic HBV infection,VIR-2218 with or without pegylated interferon-alpha-2a,not specified,"HBsAg seroclearance, adverse events","open-label, phase 2 study",False,"Population does not have hepatocellular carcinoma, and study design is not an RCT."
317,patients with small hepatocellular carcinoma,radiofrequency ablation with a novel approach,not specified,"local tumor progression, intrahepatic remote recurrence",prospective study,False,"Intervention is not immunotherapy or targeted therapy, and study design is not an RCT."
318,patients with hepatocellular carcinoma,not specified,not specified,microvascular invasion prediction,retrospective study,False,"Intervention and comparison not specified, and study design is not an RCT."
319,patients with hepatocellular carcinoma,systemic treatment with sorafenib,not specified,progression of non-hypervascular hepatobiliary phase hypointense lesions,analysis within the SORAMIC trial,False,"Intervention is not immunotherapy or targeted therapy, and study design is not an RCT."
280,stage I and II HCC patients,liver resection,not specified,recurrence outcome,retrospective review,False,"Does not match target criteria: intervention is not immunotherapy or targeted therapy, no comparison specified, outcome is not survival or response rate, study design is not randomized controlled trial."
281,patients with cirrhosis,mailed outreach plus patient navigation for HCC screening,usual care with visit-based screening,screening process completion,multicentre pragmatic randomised clinical trial,False,"Does not match target criteria: population is not specifically HCC patients, intervention is not immunotherapy or targeted therapy, outcome is not survival or response rate."
282,patients diagnosed with hypothyroidism,not specified,not specified,frequency of cancer,"observational, retrospective study",False,"Does not match target criteria: population is not HCC patients, no intervention or comparison specified, outcome is not survival or response rate, study design is not randomized controlled trial."
283,patients with HCC,systemic and locoregional therapies,not specified,impact of AEs on QoL,analysis of data from the SARAH randomized controlled trial,False,"Does not match target criteria: intervention is not specifically immunotherapy or targeted therapy, no comparison specified, outcome is not survival or response rate."
284,patients with recurrent HCC,RFA in combination with toripalimab (anti-PD-1),RFA alone,recurrence free survival,not specified,True,"Matches target criteria: population is HCC patients, intervention includes immunotherapy, comparison is standard therapy, outcome is survival, though study design is not explicitly stated as randomized controlled trial."
285,patients with primary liver cancer,not specified,not specified,diagnostic and prognostic biomarker evaluation,observational study,False,"Does not match target criteria: no intervention or comparison specified, outcome is not survival or response rate, study design is not randomized controlled trial."
286,CNLC-IIIb stage HCC patients,hepatectomy in combination with apatinib and camrelizumab,not specified,patient mortality,multicentre phase II trial with single-arm,False,"Does not match target criteria: no comparison specified, study design is not randomized controlled trial."
287,Japanese NAFLD patients,not specified,not specified,liver-related events,observational study,False,"Does not match target criteria: population is not HCC patients, no intervention or comparison specified, outcome is not survival or response rate, study design is not randomized controlled trial."
288,liver cancer patients undergoing hepatectomy,not specified,not specified,severe postoperative pleural effusion,retrospective observational study,False,"Does not match target criteria: no intervention or comparison specified, outcome is not survival or response rate, study design is not randomized controlled trial."
289,outpatients at an academic tertiary care centre,not specified,not specified,sensitivity and specificity of SLE classification criteria,prospective and retrospective observational cohort study,False,"Does not match target criteria: population is not HCC patients, no intervention or comparison specified, outcome is not survival or response rate, study design is not randomized controlled trial."
250,patients with hepatocellular carcinoma (HCC) with severe pain,Transcutaneous electrical acupoint stimulation (TEAS),control group,"Numerical Rating Scale (NRS) score, Brief Pain Inventory scores, analgesic dose, frequency of opioid-induced gastrointestinal side effects, Karnofsky Performance Status (KPS), Quality of Life Scale - Liver Cancer (QOL-LC), and Brief Fatigue Inventory (BFI) scores",randomized controlled trial,False,"Population matches, but intervention is not immunotherapy or targeted therapy, and outcomes do not include survival or response rate."
251,"patients with advanced hepatocellular carcinoma (HCC), Child-Pugh A and B",Low-energy electromagnetic fields (EMFs) exposure,standard care,"safety, hemodynamic variability patterns, health-related quality of life (HRQoL), overall survival (OS), and objective response rate (ORR)",single-site feasibility trial,False,"Population matches, but intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
252,HCC patients who had curative resection,not specified,not specified,serum levels of PIVKA-II and AFP,"multicenter, retrospective, and observational study",False,"Population matches, but intervention, comparison, and outcomes do not match the target criteria, and study design is not a randomized controlled trial."
253,HCC patients undergoing hepatectomy,2D-SWE assessing LS and spleen area (SPA),not specified,prediction of posthepatectomy liver failure (PHLF),multicenter observational study,False,"Population matches, but intervention, comparison, and outcomes do not match the target criteria, and study design is not a randomized controlled trial."
254,patients with hepatocarcinoma,sorafenib,not specified,"overall survival, time to progression, and response using RECIST criteria",observational retrospective study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, comparison is not specified, and study design is not a randomized controlled trial."
255,patients with advanced HCC in whom previous ICI therapy has failed,"stereotactic body RT (SBRT), sintilimab and IBI305",not specified,"objective response rate (ORR), disease control rate, progression-free survival, overall survival and safety","open-label, single-arm, single-centre, phase 2 trial",True,"Population, intervention, and outcomes match the target criteria, but comparison is not specified and study design is not a randomized controlled trial."
256,not specified,Therapeutic Assistance and Decision algorithms for hepatobiliary tumor Boards (ADBoard),conventional MDM,"concordance of recommendations, completeness of patient information, explainability of tumor board protocols",randomized to either MDM with ADBoard or conventional MDM,False,"Population not specified, intervention does not match, and outcomes do not include survival or response rate."
257,unresectable HCC patients,hepatic arterial infusion chemotherapy (HAIC),not specified,"therapeutic response, Progression-free survival (PFS)",retrospective study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, comparison is not specified, and study design is not a randomized controlled trial."
258,patients with ulcerative colitis (UC),ritlecitinib,placebo,modified clinical remission and endoscopic improvement,phase 2b trial,False,"Population does not match, and study design is not a randomized controlled trial."
259,patients with centrally located hepatocellular carcinoma,augmented reality navigation (ARN) and fluorescence imaging,non-ARN-FI group,perioperative outcomes and disease-free survival,post hoc analysis of an original nonrandomized clinical trial,False,"Population matches, but intervention does not match, and study design is not a randomized controlled trial."
320,patients with hepatocellular carcinoma,pre-TACE 3D CT angiography,DSA,detection of HCC feeding vessels,prospective study,False,Intervention and outcome do not match target criteria.
321,"patients with liver, lung, and kidney tumors",high-power microwave ablation,not specified,"technical success, safety, and effectiveness",retrospective observational study,False,"Population and intervention partially match, but comparison and outcome do not match target criteria."
322,UICC7 Stage IIIA and IIIB potentially resectable HCC patients,preoperative chemotherapy,upfront resection,overall survival rate,phase II clinical trial,False,"Intervention and outcome partially match, but population and study design do not fully match target criteria."
323,patients undergoing elective resection for HCC,hepatic resection,not specified,90-day mortality,retrospective study,False,"Population and outcome partially match, but intervention and comparison do not match target criteria."
324,Chinese chronic liver disease and severe thrombocytopenia patients,lusutrombopag,placebo,platelet count increase and safety,"double-blind, parallel-group phase 3 study",False,Population and intervention do not match target criteria.
325,unresectable hepatocellular carcinoma patients,atezolizumab plus bevacizumab,not specified,therapeutic efficacy and progression-free survival,retrospective observational study,False,"Population and intervention partially match, but comparison and study design do not match target criteria."
326,adult patients with solid tumors treated with cisplatin,cisplatin-based systematic chemotherapy,not specified,incidence and risk factors for CIA and long-term renal dysfunction,"retrospective, single-center, observational, longitudinal follow-up study",False,Population and intervention do not match target criteria.
327,patients with hepatocellular carcinoma,COVID-19 vaccination,not specified,infection-free survival,"prospective, multicenter, observational cohort study",False,"Population and outcome partially match, but intervention and comparison do not match target criteria."
328,patients with small- and medium-sized HCC,microwave ablation and radiofrequency ablation,not specified,therapeutic response and clinical outcome,prospective trial,False,"Population and intervention partially match, but comparison and outcome do not match target criteria."
329,patients diagnosed with HRS undergoing liver transplant,terlipressin,"non-HRS, non-hepatocellular carcinoma cirrhotic indications",post-transplant renal function and survival,"retrospective, observational study",False,Population and intervention do not match target criteria.
340,patients with NASH,"vitamin E, statins, metformin",not specified,diagnosis and management of NAFLD and NASH,cross-sectional observational study,False,Population does not match; intervention and outcome do not match target criteria; study design is not a randomized controlled trial.
341,patients with hepatocellular carcinoma after hepatitis B cirrhosis,prolonging hepatic hilum occlusion time using IPM combined with CLCVP,standard occlusion time,"operation time, postoperative parameters",randomized controlled trial,False,Population matches; intervention and comparison partially match; outcome does not match target criteria; study design matches.
342,patients treated with DAAs,DAAs treatment,not specified,incidence of EVs and HCC,observational study,False,Population does not match; intervention and outcome do not match target criteria; study design is not a randomized controlled trial.
343,subjects with suspected HCC,IOP Injection as MRI contrast agent,not specified,safety and clinical validity of IOP Injection,prospective study,False,Population matches; intervention and outcome do not match target criteria; study design is not a randomized controlled trial.
344,patients with unresectable HCC after TACE failure,iNKT cell infusion,TAE therapy without iNKT cell infusion,"PFS, OS, ORR, DCR, QoL",randomized controlled trial,True,"Population, intervention, comparison, outcome, and study design all match target criteria."
345,patients with cirrhotic HCV,sofosbuvir plus daclatasvir with ribavirin,sofosbuvir with ribavirin,sustained virological response,not specified,False,Population does not match; intervention and comparison partially match; outcome does not match target criteria; study design not specified.
346,HCC patients,disulfidptosis-related signature,not specified,"prognostic prediction, immune microenvironment",not specified,False,Population matches; intervention and outcome do not match target criteria; study design not specified.
347,cirrhotic patients,not specified,not specified,clinical characteristics of PVT,retrospective analysis,False,"Population does not match; intervention, comparison, and outcome do not match target criteria; study design is not a randomized controlled trial."
348,healthy participants,Rencofilstat,fasted vs high-fat conditions,pharmacokinetics of RCF,"phase 1, randomized, open-label study",False,Population does not match; intervention and comparison partially match; outcome does not match target criteria; study design is not a randomized controlled trial for HCC.
349,persons with chronic hepatitis B and hepatic steatosis,aerobic exercise training,no intervention,"fat fraction of the liver, hepatokine secretion, lipid- and glucose metabolism","randomized, controlled, clinical intervention trial",False,Population does not match; intervention and comparison partially match; outcome does not match target criteria; study design matches but not for HCC.
350,patients with unresectable hepatocellular carcinoma,nofazinlimab plus lenvatinib,not specified,objective responses and safety profile,"phase 1a/1b, open-label, multicenter, dose-escalation/expansion trial",False,"Population and intervention match, but comparison and study design do not meet the target criteria."
351,elderly patients with hepatocellular carcinoma,lenvatinib,younger group (<80 years old),"adverse events, administration period, dose intensity, objective response, and progression-free survival",retrospective evaluation,False,"Population and intervention match, but comparison and study design do not meet the target criteria."
352,patients with hepatocellular carcinoma undergoing transarterial chemoembolization,clinical decision support system,handbook only,"patient-centered caring attitude, pain management barrier identification, and comfort care competence",randomized controlled trial,False,"Population and study design match, but intervention and outcome do not meet the target criteria."
353,participants at risk for hepatocellular carcinoma,reduced amount of iodinated contrast medium,standard liver CT,image quality and lesion conspicuity,randomized controlled trial,False,"Population and study design match, but intervention and outcome do not meet the target criteria."
354,patients undergoing hepatectomy by laparotomy,inspiratory muscle training,conventional physical therapy,strength of the respiratory muscles and incidence of postoperative pulmonary complications,"prospective, randomized, clinical trial",False,"Population and study design match, but intervention and outcome do not meet the target criteria."
355,patients with hepatocellular carcinoma treated with immune checkpoint inhibitors,"continuation of ICI, treatment switching to TKIs, cessation of anticancer therapy",not specified,post-progression survival,retrospective observational study,False,"Population and intervention match, but comparison and study design do not meet the target criteria."
356,patients with various cancers including hepatocellular carcinoma,not specified,not specified,USP7 expression and its correlation with clinical outcomes,retrospective observational study combined with bioinformatics analysis,False,"Population, intervention, comparison, and outcome do not meet the target criteria."
357,patients diagnosed with chronic hepatitis B,not specified,not specified,"epidemiology, clinical, and economic outcomes",retrospective observational study,False,"Population, intervention, comparison, and outcome do not meet the target criteria."
358,BCLC stage B or C hepatocellular carcinoma patients,atezolizumab and bevacizumab,viral vs non-viral infection,efficacy and safety,retrospective cohort study,False,"Population and intervention match, but comparison and study design do not meet the target criteria."
359,young and middle-aged male patients with hepatocellular carcinoma,not specified,not specified,overall survival,retrospective analysis using SEER database,False,"Population and outcome match, but intervention and comparison do not meet the target criteria."
370,58 HBV-related HCC patients,expression profile of SUMO and NF-κB genes,not specified,association with clinical outcome of HCC,observational study,False,"Population matches, but intervention, comparison, outcome, and study design do not meet target criteria."
371,dogs with nonresectable hepatic carcinoma,drug-eluting bead transarterial-chemoembolization (DEB-TACE),not specified,predict median survival time,"prospective, single-arm clinical trial",False,"Population does not match, and study design is not a randomized controlled trial."
372,"35 patients with chronic liver disease, cirrhosis, or current HCC",MRI features for risk stratification,not specified,predict hypervascular transformation,retrospective observational cohort study,False,"Population matches, but intervention, comparison, outcome, and study design do not meet target criteria."
373,316 patients with HCC,contrast-enhanced ultrasound (CEUS),not specified,sonomorphological and histopathological features associated with lack of APHE,prospective multi-center real-life setting,False,"Population matches, but intervention, comparison, outcome, and study design do not meet target criteria."
374,"1,935 patients with newly diagnosed multiple myeloma",not specified,not specified,clinical characteristics and prognosis,retrospective analysis,False,"Population does not match, and intervention, comparison, outcome, and study design do not meet target criteria."
375,439 patients with extreme hyperbilirubinemia,not specified,not specified,30-day mortality,retrospective observational cohort study,False,"Population does not match, and intervention, comparison, outcome, and study design do not meet target criteria."
376,789 consecutive patients who underwent surgery for HCC,not specified,not specified,clinical characteristics and surgical outcomes,retrospective analysis,False,"Population matches, but intervention, comparison, outcome, and study design do not meet target criteria."
377,321 patients with advanced chronic liver disease caused by HCV,direct-acting antivirals (DAAs),not specified,development of liver-related events after SVR,"observational, retrospective study",False,"Population does not match, and study design is not a randomized controlled trial."
378,"188,770 individuals with an alcohol-related hospital presentation",not specified,not specified,all-cause and cause-specific mortality,observational study,False,"Population does not match, and intervention, comparison, outcome, and study design do not meet target criteria."
379,127 patients undergoing elective liver cancer resection and splenectomy,US transducer-guided radial artery puncture technology with guide marks,conventional US transducer-guided radial artery puncture technology,success rate of radial artery cannulation,parallel-group trial,False,"Population does not match, and outcome does not meet target criteria."
330,patients with beyond-the-Milan criteria HCC,combination TACE and RFA therapy,TACE monotherapy,"1-month tumour response, progression-free survival, overall response rate, number of treatments until CR, overall survival, and change in liver function",randomized controlled trial,False,"Population and intervention match, but the comparison is not standard therapy or placebo, and outcomes include more than survival or response rate."
331,advanced PHC patients,TACE combined with radioactive iodine implantation therapy,TACE alone,"tumor lesion length, clinical effect, serum AFP, CT perfusion parameters, survival time",randomized controlled trial,False,"Population and intervention match, but the comparison is not standard therapy or placebo, and outcomes include more than survival or response rate."
332,patients with hepatocellular carcinoma,diffusion-weighted imaging with apparent diffusion coefficient map,not specified,predictive performance of imaging in predicting proliferation rate,single-center retrospective study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, no comparison specified, outcome not survival or response rate, and study design is not a randomized controlled trial."
333,cirrhotic patients with HCC,gadoxetic acid-enhanced MRI,contrast-enhanced Computed Tomography,diagnostic performance for HCC detection and liver transplant eligibility assessment,"prospective, single-institution study",False,"Population matches, but intervention is not immunotherapy or targeted therapy, outcome not survival or response rate, and study design is not a randomized controlled trial."
334,patients with hepatocellular carcinoma,carbon ion radiotherapy,not specified,"maximum tolerated dose, overall survival, local progression-free survival, progression-free survival",dose escalation study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, no comparison specified, outcome includes more than survival or response rate, and study design is not a randomized controlled trial."
335,patients with HCC undergoing narrow-margin hepatectomy,postoperative radiotherapy,narrow-margin hepatectomy alone,"overall survival, disease-free survival, recurrence rates",two-arm cohort study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, outcome includes more than survival or response rate, and study design is not a randomized controlled trial."
336,patients with HCC scheduled for locoregional treatment,3D-CEUS/MRI-CEUS fusion imaging,2D-CEUS,diagnostic accuracy in assessing treatment response,multicenter prospective study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, outcome not survival or response rate, and study design is not a randomized controlled trial."
337,inpatients with poorly controlled diabetes,not specified,not specified,CA19-9 levels,retrospective cohort study,False,"Population does not match, intervention not specified, no comparison specified, outcome not survival or response rate, and study design is not a randomized controlled trial."
338,chronic hepatitis C patients,direct-acting antiviral treatments,not specified,sustained virological response rates,"retrospective, observational study",False,"Population does not match, intervention is not immunotherapy or targeted therapy, no comparison specified, outcome not survival or response rate, and study design is not a randomized controlled trial."
339,HCC patients undergoing liver transplantation,no-touch technique in LT,conventional LT technique,"disease-free survival, overall survival",prospective randomized controlled trial,False,"Population matches, but intervention is not immunotherapy or targeted therapy, outcome includes more than survival or response rate, and study design is a randomized controlled trial but does not match the target criteria."
390,patients with HCCs >3 cm,combination therapy using transarterial chemoembolization with microwave ablation,MWA monotherapy,"primary treatment efficacy, local tumor progression, tumor control rate, and overall survival",retrospective observational study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
391,healthy Chinese male volunteers,donafenib,not specified,"absorption, metabolism, and excretion of donafenib",not specified,False,"Population does not match, and there is no comparison or outcome related to survival or response rate."
392,"participants with metastatic non-small cell lung cancer, extensive-stage SCLC or Child Pugh A unresectable hepatocellular carcinoma",atezolizumab,local standard-of-care support with/without the Roche DPM Module,health outcomes and healthcare resource usage,"interventional, open-label, multicountry platform study",False,"Population partially matches, but the study design is not a randomized controlled trial and the outcome is not directly related to survival or response rate."
393,patients with liver and gall bladder masses,FNAC and cell block method,not specified,cytological diagnosis,observational study,False,"Population does not match, and there is no comparison or outcome related to survival or response rate."
394,patients with small HCC,novel electrode system for RFA,not specified,technical efficacy and complication,"prospective, single-center clinical trial",False,"Population matches, but intervention is not immunotherapy or targeted therapy, and there is no comparison or outcome related to survival or response rate."
395,HCV-infected patients,DAAs,not specified,liver fibrosis regression,"observational, single-center, and cohort study",False,"Population does not match, and there is no comparison or outcome related to survival or response rate."
396,patients with various liver diseases,liver transplantation,not specified,overall survival rates,retrospective observational study,False,"Population partially matches, but intervention is not immunotherapy or targeted therapy, and there is no comparison or outcome related to survival or response rate."
397,patients with advanced hepatocellular carcinoma,serplulimab with or without HLX04,not specified,safety and preliminary efficacy,"open-label, multicenter phase 2 study",False,"Population and intervention match, but there is no comparison or outcome related to survival or response rate, and study design is not a randomized controlled trial."
398,early non-resectable patients with HCC,LMWA,TACE and PRFA,overall survival,retrospective multicenter observational study,False,"Population matches, but intervention is not immunotherapy or targeted therapy, and study design is not a randomized controlled trial."
399,patients who had undergone LT,not specified,not specified,overall survival and graft survival,retrospective observational study,False,"Population does not match, and there is no intervention, comparison, or outcome related to survival or response rate."
360,patients with hepatocellular carcinoma,sorafenib,supportive care,overall survival,"retrospective, single-arm, observational study",False,Study design is not a randomized controlled trial and comparison is not standard therapy or placebo.
361,patients with liver malignant tumours,ICG staining methods,positive vs negative ICG staining,"success rate of ICG staining, short-term surgical outcomes, recurrence-free survival",prospective randomised controlled superiority clinical trial,False,Population is not specifically hepatocellular carcinoma and intervention is not immunotherapy or targeted therapy.
362,Japanese patients with unresectable HCC,napabucasin plus sorafenib,not specified,"safety, pharmacokinetics, preliminary antitumor efficacy","phase I, multicenter, uncontrolled, open-label study",False,Study design is not a randomized controlled trial and comparison is not standard therapy or placebo.
363,patients with HBV-related HCC after liver transplantation,ETV vs TDF,ETV group vs TDF group,HCC recurrence and overall death,multicenter observational study,False,Study design is not a randomized controlled trial and intervention is not immunotherapy or targeted therapy.
364,patients with HCC,IRE vs RFA,IRE vs RFA,"progress-free survival, overall survival","multicenter, randomized, parallel-controlled non-inferiority clinical trial",True,"Matches all PICOS criteria: population is HCC patients, intervention is IRE (a form of targeted therapy), comparison is RFA (standard therapy), outcomes are survival rates, and study design is a randomized controlled trial."
365,unresectable HCC patients,HAIC combined with donafenib,HAIC alone,"disease control rate, objective response rate, progression-free survival",randomized controlled trial,True,"Matches all PICOS criteria: population is HCC patients, intervention is HAIC combined with donafenib (targeted therapy), comparison is HAIC alone (standard therapy), outcomes include survival and response rates, and study design is a randomized controlled trial."
366,patients with liver metastases of extrahepatic malignancies,PTX and UDCA,medication vs control arm,reduction of radiation-induced liver toxicity,prospective randomized study,False,Population is not hepatocellular carcinoma and intervention is not immunotherapy or targeted therapy.
367,HCC Egyptian patients,TACE,not specified,response to TACE,prospective cohort study,False,Study design is not a randomized controlled trial and comparison is not standard therapy or placebo.
368,non-cirrhotic adults with chronic HCV infection,sofosbuvir/velpatasvir,8 weeks vs 12 weeks of treatment,treatment response,"multicentric, randomized, open-label, non-inferiority trial",False,Population is not hepatocellular carcinoma and intervention is not immunotherapy or targeted therapy.
369,unresectable HCC patients,"lenvatinib, programmed death-1 inhibitors plus TACE",not specified,"overall survival, progression-free survival",prospective observational study,False,Study design is not a randomized controlled trial and comparison is not standard therapy or placebo.
380,patients with advanced solid tumors,"INCB062079, an oral, selective, FGFR4 inhibitor",not specified,"safety, tolerability, and preliminary efficacy",phase I study,False,Population does not specifically target hepatocellular carcinoma; no comparison to standard therapy or placebo; outcomes do not focus on survival or response rate.
381,patients with advanced hepatocellular carcinoma,HAIC plus regorafenib,regorafenib alone,"overall survival, progression-free survival, overall response rate",randomized controlled phase III trial,True,"Population, intervention, comparison, outcomes, and study design all match the target criteria."
382,patients with chronic hepatitis B on nucleoside analogue therapy,virtual monitoring clinic,standard follow-up by doctors,"therapy adherence, incidence of virological breakthrough, hepatocellular carcinoma development",randomized study,False,Population does not specifically target hepatocellular carcinoma; intervention is not immunotherapy or targeted therapy.
383,adults with metabolic dysfunction-associated steatohepatitis,not specified,non-MASH population,clinical and economic burdens,"observational, retrospective study",False,Population does not specifically target hepatocellular carcinoma; no intervention specified; study design is not a randomized controlled trial.
384,male adults suspected of having focal nodular hyperplasia,not specified,not specified,management and diagnosis of suspected FNH,retrospective study,False,Population does not specifically target hepatocellular carcinoma; no intervention or comparison specified; study design is not a randomized controlled trial.
385,patients with early hepatocellular carcinoma,radiofrequency ablation,percutaneous ethanol injection,"cost-effectiveness, complete response rate, complication rate",prospective single-center randomized trial,True,"Population, intervention, comparison, outcomes, and study design all match the target criteria."
386,patients with diabetic foot ulcers,spinal cord stimulation,endovascular revascularization,"quality of life, pain relief, lower limb skin temperature, blood flow, nerve conduction",retrospective analysis,False,Population does not specifically target hepatocellular carcinoma; intervention is not immunotherapy or targeted therapy; study design is not a randomized controlled trial.
387,naïve cirrhotic Egyptian patients infected with HCV-G4,sofosbuvir with daclatasvir or sofosbuvir with simeprevir plus ribavirin,not specified,"safety, efficacy, sustained virological response rates",randomized study,False,Population does not specifically target hepatocellular carcinoma; no comparison to standard therapy or placebo.
388,patients undergoing living donor liver transplantation,not specified,not specified,relationship between preoperative serum uric acid level and postoperative acute kidney injury,prospective observational study,False,Population does not specifically target hepatocellular carcinoma; no intervention or comparison specified; study design is not a randomized controlled trial.
389,patients with chronic hepatitis C who achieved sustained virologic response after DCV/ASV treatment,not specified,not specified,hepatocellular carcinoma occurrence,multicenter prospective observational study,False,Population does not specifically target hepatocellular carcinoma; no intervention or comparison specified; study design is not a randomized controlled trial.
410,patients with advanced solid tumors,iparomlimab (immunotherapy),not specified,"objective response rate, progression-free survival, overall survival","open-label, phase 1c study",False,"Population does not match (hepatocellular carcinoma not specified), comparison not specified, study design not randomized controlled trial"
411,patients post-liver transplantation for HCC,calcineurin-based vs. mammalian target of rapamycin inhibitors-based immunosuppression,calcineurin inhibitors vs. sirolimus,HCC recurrence risk stratification,randomized clinical trial,False,"Population matches, intervention and comparison are related to immunosuppression not directly to immunotherapy or targeted therapy for HCC, outcome does not directly match (survival or response rate not specified)"
412,patients with chronic hepatitis B,entecavir vs. tenofovir alafenamide,ETV vs. TAF,"efficacy, safety, incidence of HCC","nonrandomized, prospective, observational analysis",False,"Population does not match (hepatocellular carcinoma not specified), intervention and comparison not related to immunotherapy or targeted therapy, study design not randomized controlled trial"
400,not specified,not specified,not specified,not specified,methodological review,False,"Does not specify hepatocellular carcinoma patients, immunotherapy or targeted therapy, standard therapy or placebo, survival or response rate, or randomized controlled trial design."
401,patients with advanced HCC,bintrafusp alfa,not specified,"objective response rate, safety, and pharmacokinetics","open-label, phase I study",False,"Specifies hepatocellular carcinoma patients and targeted therapy but lacks comparison to standard therapy or placebo, and is not a randomized controlled trial."
402,patients with cirrhosis and PVT,not specified,not specified,90-day LT-free mortality,post hoc analysis of prospective cohorts,False,"Does not specify hepatocellular carcinoma patients, immunotherapy or targeted therapy, standard therapy or placebo, survival or response rate, or randomized controlled trial design."
403,patients scheduled for major liver resection,not specified,not specified,"postoperative morbidity, ICU and hospital stay, survival","prospective, observational study",False,"Does not specify hepatocellular carcinoma patients, immunotherapy or targeted therapy, standard therapy or placebo, survival or response rate, or randomized controlled trial design."
404,health care workers in tertiary care hospital,not specified,not specified,hand hygiene compliance,"prospective, observational study",False,"Does not specify hepatocellular carcinoma patients, immunotherapy or targeted therapy, standard therapy or placebo, survival or response rate, or randomized controlled trial design."
405,patients underwent TACE intervention,digital variance angiography,digital subtraction angiography,"contrast-to-noise ratio, image quality",retrospective study,False,"Specifies hepatocellular carcinoma patients and comparison but lacks targeted therapy, survival or response rate, and is not a randomized controlled trial."
406,patients with intrahepatic mass-forming cholangiocarcinoma,not specified,not specified,microvascular invasion prediction,retrospective study,False,"Does not specify hepatocellular carcinoma patients, immunotherapy or targeted therapy, standard therapy or placebo, survival or response rate, or randomized controlled trial design."
407,patients with HCC or FNH,Gd-EOB-DTPA enhanced MRI,not specified,differential diagnosis accuracy,retrospective study,False,"Specifies hepatocellular carcinoma patients but lacks targeted therapy, standard therapy or placebo, survival or response rate, and is not a randomized controlled trial."
408,patients with hepatocellular carcinoma,transradial access versus transfemoral access in c-TACE,transfemoral access,"operators radiations exposure, patients comfort, technical success",multicenter prospective study,False,"Specifies hepatocellular carcinoma patients and comparison but lacks targeted therapy, survival or response rate, and is not a randomized controlled trial."
409,solid organ transplant recipients with SARS-CoV-2 infection,prednisone monotherapy,not specified,"drug-drug interactions, efficacy, safety",observational study,False,"Does not specify hepatocellular carcinoma patients, immunotherapy or targeted therapy, standard therapy or placebo, survival or response rate, or randomized controlled trial design."
